May 17, 2020

ReWalk Robotics signs new agreement with Harmonie Médical Service

Catherine Sturman
3 min
ReWalk Robotics Ltd has recently signed an agreement with French company Harmonie Médical Service (HMS) to enable the distribution of the exoskeleton s...

ReWalk Robotics Ltd has recently signed an agreement with French company Harmonie Médical Service (HMS) to enable the distribution of the exoskeleton systems for individuals with spinal cord injuries (SCI), paraplegia or incomplete paralysis of the legs within France.

ReWalk Robotics are responsible for the design and development of exoskeletons which allow wheelchair-bound individuals with mobility impairments or other medical conditions to stand and walk again. It is also the first exoskeleton to receive FDA clearance for personal and rehabilitation use within the US. 

HMS on the other hand is one of the largest medical device providers in France. The company will be distributing ReWalk’s Personal systems for use in the home and community, and ReWalk Rehabilitation in clinical rehabilitation settings of providers working with individuals with SCI.

With headquarters in the US, Israel and Germany, ReWalk’s robotic exoskeletons improve the quality of life for individuals with lower limb disability through these technologies.

"The partnership with HMS provides an ideal structure to allow paralyzed individuals throughout France the ability to walk again," said Jodi Gricci, Chief Commercial Officer of ReWalk Robotics.

"As the product is now available for everyday use at home and in the community, HMS provides the resources, support structure and quality as a leading provider of products for injured individuals."

Related Stories

Established in 1789, HMS offers a wide range of products, including disability and mobility, medical equipment, comfort items, technical aids for home care, community health facilities,orthopaedics, physiotherapy and management vehicles. The distribution agreement with ReWalk will therefore apply to all of the HMS offices across France.

"Our partnership with ReWalk is a real opportunity for HMS," said Sébastien Chamereau, Head of Disability Activity for Harmonie Médical Service. "We have been working for 30 years in the medical materials domain with people who have lost their mobility. We have always looked for innovative technologies in this domain, especially with the arrival of the first stand-up wheelchairs and, later, intelligent control systems.

“Our goal is to provide maximum autonomy to our customers in their everyday lives. The ReWalk 6.0 offers new medical and social opportunities to individuals with spinal cord injury.”

Additionally, the company has also developed a soft suit exoskeleton for stroke patients. Called Restore, the exoskeleton will improve patients’ quality of life and current mobility issues, and is set for release in 2018.

Built in collaboration with the Wyss Institute, CEO Larry Jasinski explained: “We are eager to begin clinical studies and pursue regulatory approvals so that these systems can be provided to millions of patients who can benefit from access to the device.” With three million stroke survivors with lower limb disability situated in the US, the company is sure to gain ground in this space.

Share article

Jun 18, 2021

Skin Analytics wins NHSX award for AI skin cancer tool 

2 min
Skin Analytics uses AI to detect skin cancer and will be deployed across the NHS to ease patient backlogs

An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system. 

NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion. 

Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making. 

In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog. 

Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening. 

DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.

Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.

Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges. 

"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”

Share article